SC takes action against Andhra Pradesh, Delhi, and J&K for failing to regulate misleading ads: Report

Hearing a written petition filed by the Indian Medical Association, the SC asked the chief secretaries of the three states to explain why they failed to file an affidavit

By  Storyboard18Feb 11, 2025 11:41 AM
SC takes action against Andhra Pradesh, Delhi, and J&K for failing to regulate misleading ads: Report
Andhra Pradesh, Delhi, and J&K have failed to comply with the SC's order on misleading ads.

The Supreme Court of India has taken action against the authorities of Andhra Pradesh, Jammu, Kashmir, and Delhi for failing to take action against misleading advertisements on Ayurvedic medicines.

The apex court summoned the chief secretaries of the three states, and the next hearing is scheduled for March 7.

The court said the states had not submitted an affidavit on compliance with Rule 170 but had shown that they implemented the rule.

Rule 170 of the Drugs and Cosmetics Rules grants authorities power to act against misleading advertisements of Ayurvedic medicines.

Hearing a written petition filed by the Indian Medical Association, the SC asked the chief secretaries of the three states to explain why they failed to file an affidavit.

According to a report by LiveLaw, a bench of Justices Abhay S Oka and Ujjal Bhuyan said that the Supreme Court had asked the states to implement Rule 170 of the Drugs and Cosmetics Rules, 1945.

"We find that there is hardly any implementation of the orders passed by this Court...We direct the states of Andhra Pradesh, Delhi, Goa, Gujarat, Jammu, and Kashmir to file further affidavits, including affidavits dealing with enforcement of Rule 170," the judges said, as per the LiveLaw report.

Last year, on 27 May, the Supreme Court directed all states and union territories to file affidavits of their Licensing authorities regarding action taken by them since 2018 in respect of misleading ads that violate the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Drugs and Cosmetics Act, 1940 and Consumer Protection Act, 2019.

This year, the court issued a warning that it would initiate contempt proceedings against states/UTs that failed to take action against the misleading ads and medical claims running contrary to the law.

As per the latest hearing of the SC, Andhra Pradesh, Delhi, and J&K have failed to comply with the court's order.

First Published on Feb 11, 2025 11:41 AM

More from Storyboard18

Advertising

FMCG major ITC cuts ad spend to Rs 1,331 crore in FY25

FMCG major ITC cuts ad spend to Rs 1,331 crore in FY25

Advertising

Truecaller launches ‘Play’; aims to redefine mobile advertising with immersive, video-first formats

Truecaller launches ‘Play’; aims to redefine mobile advertising with immersive, video-first formats

Advertising

Cannes Lions withdraws Grand Prix after discovery of AI-faked case film; introduces stricter rules for AI disclosure

Cannes Lions withdraws Grand Prix after discovery of AI-faked case film; introduces stricter rules for AI disclosure

How it Works

Google launches "Offerwall" as AI summaries impact publisher ad income

Google launches "Offerwall" as AI summaries impact publisher ad income

Advertising

Ad holding giants go on a shopping spree for Influencer Marketing firms

Ad holding giants go on a shopping spree for Influencer Marketing firms

Brand Marketing

Rosé and redundancies: Big tech, big ad spend, and the cost of Cannes amid mass layoffs

Rosé and redundancies: Big tech, big ad spend, and the cost of Cannes amid mass layoffs

Brand Marketing

Colgate India ramps up brand building, automation; Ad spends hit Rs 822 crore in FY25

Colgate India ramps up brand building, automation; Ad spends hit Rs 822 crore in FY25

How it Works

FSSAI’s alco-bev standard amendments open doors for innovation, but also creative avenues for surrogate ads

FSSAI’s alco-bev standard amendments open doors for innovation, but also creative avenues for surrogate ads